ArticleMed (New York, N.Y.)2020
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.
Article in Med (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04370262 (A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care), which is not on this map. Cited by 385 papers, 23 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults
Who cites it
385 citing papers in PubMed, 23 syntheses or guidelines pooled it.
- Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis.PloS one · 2022Pooled it
- Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials.Scientific reports · 2021Pooled it
- The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7).Addiction (Abingdon, England) · 2021Pooled it
- Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations.Trials · 2021Pooled it
- Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Pooled it
- Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.Pathogens and global health · 2021Pooled it
- Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2021Pooled it
- Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials.Journal of medical virology · 2021Pooled it
- From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?Journal of travel medicine · 2021Pooled it
- Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.Journal of medical virology · 2021Pooled it
- Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients.Journal of the Chinese Medical Association : JCMA · 2021Pooled it
- Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Pooled it
- Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Pooled it
- Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2021Pooled it
- Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19.Current cardiology reviews · 2021Pooled it
- A systematic review assessing the under-representation of elderly adults in COVID-19 trials.BMC geriatrics · 2020Pooled it
- A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment.Scientific reports · 2020Pooled it
- Pooled it
- Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Guideline
- Pooled it
325 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
backgroundDespite limited and conflicting evidence, hydroxychloroquine, alone or in combination with azithromycin, is widely used in COVID-19 therapy.
methodsWe performed a retrospective study of electronic health records of patients hospitalized with confirmed SARS-CoV-2 infection in US Veterans Health Administration medical centers between March 9, 2020 and April 29, 2020. Patients hospitalized within 24 h of diagnosis were classified based on their exposure to hydroxychloroquine alone (HC) or with azithromycin (HC+AZ) or no HC as treatments. The primary outcomes were mortality and use of mechanical ventilation.
findingsA total of 807 patients were evaluated. Compared to the no HC group, after propensity score adjustment for clinical characteristics, the risk of death from any cause was higher in the HC group (adjusted hazard ratio [aHR], 1.83; 95% confidence interval [CI], 1.16-2.89; p = 0.009), but not in the HC+AZ group (aHR, 1.31; 95% CI, 0.80-2.15; p = 0.28). Both the propensity-score-adjusted risks of mechanical ventilation and death after mechanical ventilation were not significantly different in the HC group (aHR, 1.19; 95% CI, 0.78-1.82; p = 0.42 and aHR, 2.11; 95% CI, 0.96-4.62; p = 0.06, respectively) or in the HC+AZ group (aHR, 1.09; 95% CI, 0.72-1.66; p = 0.69 and aHR, 1.25; 95% CI, 0.59-2.68; p = 0.56, respectively) compared to the no HC group.
conclusionsAmong patients hospitalized with COVID-19, this retrospective study did not identify any significant reduction in mortality or in the need for mechanical ventilation with hydroxychloroquine treatment with or without azithromycin.
fundingUniversity of Virginia Strategic Investment Fund.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.